CHICAGO--(BUSINESS WIRE)-- Xeris Pharmaceuticals, Inc. (Nasdaq: XERS), a specialty pharmaceutical company leveraging its novel formulation technology platforms to develop and commercialize ...

CHICAGO--(BUSINESS WIRE)-- Xeris Pharmaceuticals, Inc. (Nasdaq: XERS), a specialty pharmaceutical company leveraging its novel formulation technology platforms to develop and commercialize ...

Revenue: Net sales for Gvoke PFS for both the fourth quarter and full year 2019 were $1.6 million. Grant and other income was $0.2 million for the fourth quarter and $1.1 million for the full year ...

Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a biopharmaceutical company developing and commercializing unique therapies for patient populations in endocrinology, neurology, and gastroenterology, ...

Continuing to execute commercial build and launch readiness for Gvoke HypoPen™ and Gvoke PFS™ Dosed first patient in a Phase 2 study evaluating ready-to-use (RTU) glucagon in EIH Advancing diazepam to ...

CHICAGO--(BUSINESS WIRE)--Xeris Pharmaceuticals, Inc. (Nasdaq: XERS), a pharmaceutical company leveraging its novel formulation technology platforms to develop and commercialize ready-to-use ...

Xeris Pharmaceuticals Inc. (NASDAQ: XERS) shares were halted briefly on Tuesday after the firm announced that it has received regulatory approval from the U.S. Food and Drug Administration (FDA) for ...

Xeris Pharmaceuticals, a specialty pharmaceutical company has received the Food and Drug Administration’s blessing for Gvoke (glucagon) injection, a ready-to-use, room-temperature stable liquid ...

CHICAGO-- (BUSINESS WIRE)--Xeris Pharmaceuticals, Inc. (Nasdaq: XERS), a specialty pharmaceutical company leveraging its novel formulation technology platforms to develop and commercialize ...

* XERIS PHARMACEUTICALS - $0 COPAY CARD IS AVAILABLE TO COMMERCIALLY INSURED PATIENTS, WHO MAY OR MAY NOT HAVE GVOKE PFS COVERED BY THEIR INSURANCE PLAN Source text for Eikon: Further company coverage ...